Lung Cancer Clinical Trials in San Antonio

Showing 561-570 of 570 trials

Safety Study of XL999 in Adults With Non-Small-Cell Lung Cancer

NCT00491699

The purpose of this study is to determine the safest dose of XL999 and how well subjects with Non-Small-Cell Lung Cancer tolerate XL999. XL999 is a small molecule inhibitor of multiple kinases including VEGFR, PDGFR, FGFR, FLT-3, and Src, which are involved in tumor cell growth, formation of new blood vessels (angiogenesis), and metastasis.

Non-Small-Cell Lung Cancer

Symphony Evolution, Inc.2 participantsStarted Aug 2007

Los Angeles, California, United States • Atlanta, Georgia, United States • Detroit, Michigan, United States +2 more locations

COMPLETEDPhase 274 miles

Study Tests The Safety And Effectiveness Of SU011248 In Patients With Non-Small Cell Lung Cancer Having Brain Metastases

NCT00372775

This study will evaluate the safety, tolerability and efficacy of SU011248 in patients with non-small cell lung cancer with brain metastases.

Non-Small Cell Lung Cancer

Pfizer66 participantsStarted Mar 2007

Norwalk, Connecticut, United States • Cocoa Beach, Florida, United States • Merritt Island, Florida, United States +24 more locations

Safety Study of XL999 in Adults With Non-Small-Cell Lung Cancer

Study Tests The Safety And Effectiveness Of SU011248 In Patients With Non-Small Cell Lung Cancer Having Brain Metastases

Lung Cancer Trials in Other Cities

Study Comparing Amrubicin Versus Topotecan in Patients With Small Cell Lung Cancer Who Have Responded to Prior Therapy.

Picoplatin as Second-Line Therapy for Patients With Small Cell Lung Cancer

Study of Talabostat and Pemetrexed vs. Pemetrexed in Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC) After Failure of Platinum-Based Chemotherapy

Phase 2 Study of VELCADE Alone or VELCADE® Plus Docetaxel in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer

STA-4783 in Combination With Paclitaxel and Carboplatin for the Treatment of Chemotherapy Naive Patients With Stage IIIB/IV Non Small Cell Lung Cancer (NSCLC)

Safety and Immunogenicity of Recombinant DNA and Adenovirus Expressing L523S Protein in Early Stage Non-Small Cell Lung Cancer

Evaluation of the Overall Survival of Meclinertant Versus Placebo After a First Line Chemotherapy With Cisplatin + Etoposide

Safety and Immune Response to a Multi-component Immune Based Therapy (MKC1106-PP) for Patients With Advanced Cancer.

Other Conditions in San Antonio